TIVC News & Events

Tivic Health Systems announced it is changing its corporate name to "Valion Bio" and its Nasdaq ticker symbol from "TIVC" to "VBIO," effective at market open on Tuesday, April 28. The CUSIP number for the company's common stock will remain unchanged. The rebrand is not merely cosmetic. It reflects the completion of a fundamental strategic transformation - the deliberate unwinding of a consumer medical device business and its replacement with a focused late-stage biopharmaceutical platform anchored by a government-priority asset with over 15 years and more than $140M in cumulative development investment, and supported by a wholly owned biomanufacturing subsidiary.

Tivic Health files to sell 956,222 shares of common stock for holders

Tivic Health Systems announced it has received a formal Request for Information, RFI, from the Ukrainian Ministry of Health. The RFI initiates the formal evaluation of Entolimod Tivic's late-stage Toll-like Receptor 5 agonist for potential inclusion in Ukraine's national strategic reserves as a countermeasure against Acute Radiation Syndrome. Additionally, the Ukrainian Ministry of Health has requested to schedule a pre-submission meeting for Entolimod. "Tivic's Entolimod, from our TLR5 platform, has catalyzed significant interest from international governments that recognize its potential as a cornerstone of national preparedness," said Michael K. Handley, chief executive officer of Tivic. "We are working closely with the Ukrainian Ministry of Health to establish a pathway toward potential accelerated approval and a formal stockpiling agreement. Our goal is to provide a superior therapeutic solution that addresses the complex requirements of regional security and patient survival."

Tivic Health Systems announced it has entered into an agreement with the National Institute of Allergy and Infectious Diseases, NIAID, part of the National Institutes of Health, to sponsor and conduct a series of preclinical studies evaluating Entolimod for gastrointestinal acute radiation syndrome, GI-ARS. The program is expected to support Tivic's development strategy for Entolimod as a medical countermeasure for acute radiation syndrome. Under the agreement, NIAID will fund and conduct GI-ARS studies, the first of which will be performed at the Armed Forces Radiobiology Research Institute